Loading organization details...
Loading organization details...
BANNER HEALTH'S NONPROFIT MISSION IS "MAKING HEALTH CARE EASIER, SO LIFE CAN BE BETTER".
Source: IRS Form 990 (Tax Year 2024)
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$10.8B
Program Spending
91%
of total expenses go to program services
Total Contributions
$370.3M
Total Expenses
▼$9.3B
Total Assets
$17.7B
Total Liabilities
▼$7.7B
Net Assets
$9.9B
Officer Compensation
→$50.3M
Other Salaries
$3.6B
Investment Income
$536.2M
Fundraising
▼N/A
Tax Year 2024 · Source: IRS Form 990, Schedule I (Grants and Other Assistance)
Total grants awarded: $69.3M
| Recipient | Location | Amount | Type | Purpose |
|---|---|---|---|---|
UNIVERSITY OF ARIZONA86-6050388 | TUCSON, AZ | $67.3M | Cash | GENERAL SUPPORT |
MCKEE WELLNESS FOUNDATION74-2182919 | LOVELAND, CO | $325K | Cash | GENERAL SUPPORT |
PERIMETER BICYCLING ASSN OF AM86-0830696 | TUCSON, AZ | $175K | Cash | GENERAL SUPPORT |
AMERICAN CANCER SOCIETY84-1316555 | PHOENIX, AZ | $170.1K | Cash | GENERAL SUPPORT |
| BETHESDA, MD | $125K | Cash | GENERAL SUPPORT | |
SCHOOL CHOICE ARIZONA20-4879504 | CHANDLER, AZ | $120K | Cash | GENERAL SUPPORT |
GREELEY INDEPENDENCE STAMPEDE84-0722231 | GREELEY, CO | $57.3K | Cash | GENERAL SUPPORT |
BANNER HEALTH FOUNDATION94-2545356 | PHOENIX, AZ | $50.5K | Cash | GENERAL SUPPORT |
CONNECT MARICOPA93-3872418 | PHOENIX, AZ | $50K | Cash | GENERAL SUPPORT |
AMERICAN HEART ASSOCIATION13-5613797 | TEMPE, AZ | $48.4K | Cash | GENERAL SUPPORT |
CHICANOS POR LA CAUSA86-0227210 | PHOENIX, AZ | $43.2K | Cash | GENERAL SUPPORT |
ALZHEIMERS ASSOCIATION13-3039601 | PHOENIX, AZ | $37.3K | Cash | GENERAL SUPPORT |
RONALD MCDONALD HOUSE CHARITIES PHOENIX86-0483792 | PHOENIX, AZ | $35K | Cash | GENERAL SUPPORT |
SUN HEALTH FOUNDATION23-7107959 | SUN CITY WEST, AZ | $35K | Cash | GENERAL SUPPORT |
GREATER PHOENIX ECONOMIC COUNCIL86-0539979 | PHOENIX, AZ | $30K | Cash | GENERAL SUPPORT |
FRIENDS OF HORSESHOE PARK27-2482871 | QUEEN CREEK, AZ | $30K | Cash | GENERAL SUPPORT |
TONTO APACHE TRIBE RECREATION86-0737973 | PAYSON, AZ | $29K | Cash | GENERAL SUPPORT |
CHANDLER COMPADRES INC99-0209180 | CHANDLER, AZ | $25K | Cash | GENERAL SUPPORT |
LIVING STREETS ALLIANCE27-4678502 | TUCSON, AZ | $25K | Cash | GENERAL SUPPORT |
SOUTHERN AZ LEADERSHIP COUNCIL86-0879845 | TUCSON, AZ | $25K | Cash | GENERAL SUPPORT |
TUCSON NURSES WEEK FOUNDATION86-0771800 | TUCSON, CO | $25K | Cash | GENERAL SUPPORT |
SCHOLARSHIP AMERICA | ST PETER, MN | $24.3K | Cash | GENERAL SUPPORT |
TORRINGTON HIGH SCHOOL83-0214502 | TORRINGTON, WY | $21.5K | Cash | GENERAL SUPPORT |
AZ CNL OF HUMAN SVC PROVIDERS86-0549096 | PHOENIX, AZ | $18.5K | Cash | GENERAL SUPPORT |
AZ HISPANIC CHAMBER OF COMMERCE86-0445372 | PHOENIX, AZ | $17.5K | Cash | GENERAL SUPPORT |
THE DAISY FOUNDATION91-2009739 | GLEN ELLEN, CA | $17.3K | Cash | GENERAL SUPPORT |
FORT COLLINS AREA CHAMBER OF COMMERCE84-0201983 | FORT COLLINS, CO | $16K | Cash | GENERAL SUPPORT |
AMERICAN TELEMEDICINE ASSOCIATION74-2676503 | PITTSBURGH, PA | $15K | Cash | GENERAL SUPPORT |
AUTISM SOCIETY OF SOUTHERN AZ47-2524160 | TUCSON, AZ | $15K | Cash | GENERAL SUPPORT |
LASSEN COMMUNITY COLLEGE | SUSANVILLE, CA | $15K | Cash | GENERAL SUPPORT |
TUCSON CONQUISTADORES INC20-2132844 | TUCSON, AZ | $15K | Cash | GENERAL SUPPORT |
SOUTHWEST PGA86-0280141 | SCOTTSDALE, AZ | $14.5K | Cash | GENERAL SUPPORT |
DIOCESAN COUNCIL FOR THE SOCIETY OF ST VINCENT DE PAUL DIOCESE PHOENIX86-0096789 | PHOENIX, AZ | $14K | Cash | GENERAL SUPPORT |
AREA AGENCY ON AGING74-2371957 | GREELEY, CO | $13.5K | Cash | GENERAL SUPPORT |
BROOKLINE COLLEGE14-1991211 | PHOENIX, AZ | $12.8K | Cash | GENERAL SUPPORT |
MARICOPA COUNTY COMM COLL DIST | Tempe, AZ | $11.7K | Cash | GENERAL SUPPORT |
EPILEPSY FOUNDATION OF AMERICA52-0856660 | BOWIE, MD | $11.5K | Cash | GENERAL SUPPORT |
MCKEE FOUNDATION74-2182919 | LOVELAND, CO | $10.4K | Cash | GENERAL SUPPORT |
AUNT RITAS FOUNDATION41-2176501 | PHOENIX, AZ | $10K | Cash | GENERAL SUPPORT |
AZ SUMMIT PUBLIC SAFETY LLC92-3120883 | PHOENIX, AZ | $10K | Cash | GENERAL SUPPORT |
COLORADO CENTER FOR THE ADVANCEMENT OF PATIENT SAFETY84-1228675 | DENVER, CO | $10K | Cash | GENERAL SUPPORT |
FC TUCSON YOUTH ACADEMY92-0957987 | TUCSON, AZ | $10K | Cash | GENERAL SUPPORT |
HONORING ARIZONAS VETERANS45-3982713 | SCOTTSDALE, AZ | $10K | Cash | GENERAL SUPPORT |
JEWISH FAMILY AND CHLDRNS SVC86-0096781 | GLENDALE, AZ | $10K | Cash | GENERAL SUPPORT |
MAKE A WISH AZ86-0409636 | SCOTTSDALE, AZ | $10K | Cash | GENERAL SUPPORT |
MESA CHAMBER OF COMME86-0038150 | MESA, AZ | $10K | Cash | GENERAL SUPPORT |
MISSION OF MERCY AZ86-0704883 | PHOENIX, AZ | $10K | Cash | GENERAL SUPPORT |
PODIUM CLUB LLC85-2923924 | CHANDLER, AZ | $10K | Cash | GENERAL SUPPORT |
SICKLE CELL FOUNDATION OF AZ46-0741040 | VAIL, AZ | $10K | Cash | GENERAL SUPPORT |
STEVEN M GOOTTER FOUNDATION20-3798976 | TUCSON, AZ | $10K | Cash | GENERAL SUPPORT |
UNITED WAY OF LARIMER COUNTY84-6031503 | FORT COLLINS, CO | $10K | Cash | GENERAL SUPPORT |
UNITED WAY OF WELD COUNTY84-6011918 | GREELEY, CO | $10K | Cash | GENERAL SUPPORT |
WASHAKIE HOSPITAL FOUNDATION83-0305783 | WORLAND, WY | $9,732 | Cash | GENERAL SUPPORT |
MEDICARE EXPO88-3458579 | PEORIA, AZ | $9,500 | Cash | GENERAL SUPPORT |
MHA FOUNDATION47-3980933 | PAYSON, AZ | $9,000 | Cash | GENERAL SUPPORT |
LASSEN JUNIOR LIVESTOCK AUCTION COMMITTEE91-1836013 | SUSANVILLE, CA | $8,890 | Cash | GENERAL SUPPORT |
EL RIO HEALTH CENTER FOUNDATION86-0816675 | TUCSON, AZ | $8,500 | Cash | GENERAL SUPPORT |
WELD LEGACY FOUNDATION84-0718355 | GREELEY, CO | $8,250 | Cash | GENERAL SUPPORT |
ST MARY'S FOOD BANK23-7353532 | PHOENIX, AZ | $7,868 | Cash | GENERAL SUPPORT |
PINAL 40 INC46-4136634 | Casa Grande, AZ | $7,750 | Cash | GENERAL SUPPORT |
AZ CH OF AMERICAN ACADEMY OF PEDIATRICS86-0917603 | PHOENIX, AZ | $7,500 | Cash | GENERAL SUPPORT |
CHECK FOR A LUMP27-4626148 | PHOENIX, AZ | $7,500 | Cash | — |
EQUALITY HEALTH FOUNDATION83-0778650 | SCOTTSDALE, AZ | $7,500 | Cash | GENERAL SUPPORT |
ASU Foundation86-6051042 | TEMPE, AZ | $6,500 | Cash | GENERAL SUPPORT |
GOSHEN COUNTY JUNIOR LIVESTOCK83-0316170 | YODER, WY | $6,447 | Cash | GENERAL SUPPORT |
TOWN OF QUEEN CREEK86-0646173 | QUEEN CREEK, AZ | $6,072 | Cash | GENERAL SUPPORT |
APACHE JUNCTION CHAMBER OF COMMERCE23-7217518 | APACHE JUNCTION, AZ | $5,800 | Cash | GENERAL SUPPORT |
TUCSON FESTIVAL OF BOOKS26-2145432 | TUCSON, AZ | $5,500 | Cash | GENERAL SUPPORT |
PLATTE COUNTY YOUTH BASEBALL82-0925491 | WHEATLAND, WY | $5,431 | Cash | GENERAL SUPPORT |
911 TOWER CHALLENGE FOUNDATION81-2701885 | TUCSON, AZ | $5,275 | Cash | GENERAL SUPPORT |
SURPRISE REGIONAL CHAMBER OF COMMERCE86-0415791 | SURPRISE, AZ | $5,150 | Cash | GENERAL SUPPORT |
PREVENT CHILD ABUSE ARIZONA86-0832901 | PRESCOTT VALLEY, AZ | $5,000 | Cash | GENERAL SUPPORT |
QUEEN CREEK SCHOOLS EDUCATION FOUNDATION20-4222581 | QUEEN CREEK, AZ | $5,000 | Cash | GENERAL SUPPORT |
| Total | $69.3M | |||
UNIVERSITY OF ARIZONA
TUCSON, AZ
$67.3M
MCKEE WELLNESS FOUNDATION
LOVELAND, CO
$325K
PERIMETER BICYCLING ASSN OF AM
TUCSON, AZ
$175K
AMERICAN CANCER SOCIETY
PHOENIX, AZ
$170.1K
BETHESDA, MD
$125K
CHANDLER, AZ
$120K
GREELEY INDEPENDENCE STAMPEDE
GREELEY, CO
$57.3K
BANNER HEALTH FOUNDATION
PHOENIX, AZ
$50.5K
CONNECT MARICOPA
PHOENIX, AZ
$50K
TEMPE, AZ
$48.4K
CHICANOS POR LA CAUSA
PHOENIX, AZ
$43.2K
PHOENIX, AZ
$37.3K
RONALD MCDONALD HOUSE CHARITIES PHOENIX
PHOENIX, AZ
$35K
SUN CITY WEST, AZ
$35K
GREATER PHOENIX ECONOMIC COUNCIL
PHOENIX, AZ
$30K
QUEEN CREEK, AZ
$30K
TONTO APACHE TRIBE RECREATION
PAYSON, AZ
$29K
CHANDLER COMPADRES INC
CHANDLER, AZ
$25K
TUCSON, AZ
$25K
SOUTHERN AZ LEADERSHIP COUNCIL
TUCSON, AZ
$25K
TUCSON NURSES WEEK FOUNDATION
TUCSON, CO
$25K
SCHOLARSHIP AMERICA
ST PETER, MN
$24.3K
TORRINGTON HIGH SCHOOL
TORRINGTON, WY
$21.5K
AZ CNL OF HUMAN SVC PROVIDERS
PHOENIX, AZ
$18.5K
AZ HISPANIC CHAMBER OF COMMERCE
PHOENIX, AZ
$17.5K
THE DAISY FOUNDATION
GLEN ELLEN, CA
$17.3K
FORT COLLINS AREA CHAMBER OF COMMERCE
FORT COLLINS, CO
$16K
AMERICAN TELEMEDICINE ASSOCIATION
PITTSBURGH, PA
$15K
TUCSON, AZ
$15K
LASSEN COMMUNITY COLLEGE
SUSANVILLE, CA
$15K
TUCSON, AZ
$15K
SOUTHWEST PGA
SCOTTSDALE, AZ
$14.5K
DIOCESAN COUNCIL FOR THE SOCIETY OF ST VINCENT DE PAUL DIOCESE PHOENIX
PHOENIX, AZ
$14K
AREA AGENCY ON AGING
GREELEY, CO
$13.5K
BROOKLINE COLLEGE
PHOENIX, AZ
$12.8K
MARICOPA COUNTY COMM COLL DIST
Tempe, AZ
$11.7K
BOWIE, MD
$11.5K
MCKEE FOUNDATION
LOVELAND, CO
$10.4K
PHOENIX, AZ
$10K
AZ SUMMIT PUBLIC SAFETY LLC
PHOENIX, AZ
$10K
COLORADO CENTER FOR THE ADVANCEMENT OF PATIENT SAFETY
DENVER, CO
$10K
FC TUCSON YOUTH ACADEMY
TUCSON, AZ
$10K
SCOTTSDALE, AZ
$10K
JEWISH FAMILY AND CHLDRNS SVC
GLENDALE, AZ
$10K
MAKE A WISH AZ
SCOTTSDALE, AZ
$10K
MESA CHAMBER OF COMME
MESA, AZ
$10K
MISSION OF MERCY AZ
PHOENIX, AZ
$10K
PODIUM CLUB LLC
CHANDLER, AZ
$10K
VAIL, AZ
$10K
TUCSON, AZ
$10K
UNITED WAY OF LARIMER COUNTY
FORT COLLINS, CO
$10K
UNITED WAY OF WELD COUNTY
GREELEY, CO
$10K
WASHAKIE HOSPITAL FOUNDATION
WORLAND, WY
$9,732
MEDICARE EXPO
PEORIA, AZ
$9,500
PAYSON, AZ
$9,000
LASSEN JUNIOR LIVESTOCK AUCTION COMMITTEE
SUSANVILLE, CA
$8,890
EL RIO HEALTH CENTER FOUNDATION
TUCSON, AZ
$8,500
WELD LEGACY FOUNDATION
GREELEY, CO
$8,250
PHOENIX, AZ
$7,868
Casa Grande, AZ
$7,750
AZ CH OF AMERICAN ACADEMY OF PEDIATRICS
PHOENIX, AZ
$7,500
PHOENIX, AZ
$7,500
EQUALITY HEALTH FOUNDATION
SCOTTSDALE, AZ
$7,500
ASU Foundation
TEMPE, AZ
$6,500
GOSHEN COUNTY JUNIOR LIVESTOCK
YODER, WY
$6,447
TOWN OF QUEEN CREEK
QUEEN CREEK, AZ
$6,072
APACHE JUNCTION, AZ
$5,800
TUCSON, AZ
$5,500
PLATTE COUNTY YOUTH BASEBALL
WHEATLAND, WY
$5,431
911 TOWER CHALLENGE FOUNDATION
TUCSON, AZ
$5,275
SURPRISE REGIONAL CHAMBER OF COMMERCE
SURPRISE, AZ
$5,150
PREVENT CHILD ABUSE ARIZONA
PRESCOTT VALLEY, AZ
$5,000
QUEEN CREEK, AZ
$5,000
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$1.8M
VA/DoD Award Count
1
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$239.3M
Awards Found
26
Department of Health and Human Services
$41.8M
ALZHEIMER'S PREVENTION INITIATIVE ADAD COLOMBIA TRIAL PROGRAM - PROJECT SUMMARY/ABSTRACT WHEN THE API AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE (ADAD) COLOMBIA TRIAL (NCT01998841) WAS ANNOUNCED IN 2012, IT LAUNCHED A NEW ERA IN AD PREVENTION RESEARCH. THE TRIAL LED US TO IDENTIFY ~6,000 PERSONS FROM THE WORLD'S LARGEST ADAD KINDRED, INCLUDING NEARLY 1,200 PRESENILIN 1 (PSEN1) E280A MUTATION CARRIERS, WHO ARE VIRTUALLY CERTAIN TO DEVELOP AD AND BECOME COGNITIVELY IMPAIRED AT 44 (SD ± 5) YEARS OF AGE; ESTABLISH THE CLINICAL TRIALS, INFUSION CAPABILITY, PET, AND MRI INFRASTRUCTURE COLOMBIA NEEDED TO CONDUCT INTERVENTIONAL STUDIES IN THE KINDRED; AND INTRODUCE PRECEDENT SETTING SCIENTIFIC, ETHICAL, SOCIAL SUPPORT, AND LOGISTICAL PARADIGMS AS WELL AS PIONEERING SAMPLE SHARING AGREEMENTS. MOREOVER, IT DEMONSTRATED THE ABILITY TO EVALUATE AN EXPERIMENTAL TREATMENT IN A VULNERABLE POPULATION FROM A DEVELOPING COUNTRY IN WAYS THAT THE PARTICIPANTS VALUED, SUCH THAT 94% OF PARTICIPANTS COMPLETED THE 5-8 YEAR TRIAL. IN RECENT LANDMARK PIVOTAL TRIALS, THE AΒ PLAQUE-CLEARING ANTIBODY (PCA) TREATMENTS LECANEMAB AND DONANEMAB WERE ASSOCIATED WITH A SIGNIFICANT CLINICAL BENEFIT IN MILDLY IMPAIRED LATE-ONSET AD (LOAD) PATIENTS, WITH DRAMATIC AΒ PET AND PLASMA PTAU REDUCTIONS, AND SIGNIFICANT EFFECTS ON OTHER AΒ, TAU, NEURODEGENERATIVE, AND INFLAMMATORY (A/T/N/I) BIOMARKERS. THESE DATA PROVIDED COMPELLING SUPPORT FOR THE ROLE OF AΒ AGGREGATES IN THE DEVELOPMENT, TREATMENT, AND PREVENTION OF AD AND SUPPORT THE USE OF BIOMARKER ENDPOINTS THAT ARE LIKELY TO BE ASSOCIATED WITH A CLINICAL BENEFIT. HERE, WE PROPOSE TO CONDUCT A TWO-PART CLINICAL TRIAL IN 200 COGNITIVELY UNIMPAIRED AND MILDLY IMPAIRED PSEN1 MUTATION CARRIERS AND 40 PLACEBO-TREATED NON-CARRIERS FROM THIS REMARKABLE KINDRED. IN PART 1, CARRIERS WILL RECEIVE UP TO 18 MONTHS OF A PLAQUE-CLEARING ANTIBODY (PCA) TREATMENT (EXEMPLAR: DONANEMAB), PERMITTING US TO COMPARE THE MAGNITUDE OF AΒ PET AND PLASMA PTAU REDUCTIONS IN THIS ADAD KINDRED TO THAT OBSERVED IN TRIALS OF THE SAME DRUG IN AΒ+ MILDLY IMPAIRED LOAD PATIENTS AND COGNITIVELY UNIMPAIRED OLDER ADULTS. IN PART 2, CARRIERS WILL BE RANDOMIZED TO RECEIVE 1) CONTINUED PCA TREATMENT, 2) AN ORAL GAMMA SECRETASE MODULATOR (GSM) TREATMENT (EXEMPLAR: RG6289) WITH THE POTENTIAL TO MINIMIZE THE RE-ACCUMULATION OF AΒ AGGREGATES IN A COMPLEMENTARY, POTENTIALLY LESS EXPENSIVE, AND MORE SCALABLE WAY, 3) COMBINED PCA/GSM TREATMENT, AND 4) PLACEBO TREATMENT FOR 18 MONTHS. THIS SEAMLESS, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-DUMMY STUDY OF A PCA AND A GSM IN COGNITIVELY UNIMPAIRED AND MCI/MILD AD PSEN1 E280A MUTATION CARRIERS WILL EFFICIENTLY ADDRESS A NUMBER OF KEY QUESTIONS INCLUDING (1) DETERMINING THE EFFICACY OF A PCA IN REDUCING BRAIN AMYLOID LEVELS IN ADAD; (2) EXAMINING THE RELATIVE EFFICACY OF COMBINATION TREATMENT FOLLOWING PCA TREATMENT VERSUS PCA MONOTHERAPY VERSUS GSM MONOTHERAPY VERSUS PLACEBO TO FURTHER LOWER OR MAINTAIN LOW BRAIN AMYLOID LEVELS AS WELL AS ON DOWNSTREAM BIOMARKERS; (3) ESTIMATING HOW LONG PLACEBO-TREATED MUTATION CARRIERS REMAIN AMYLOID NEGATIVE FOLLOWING PCA- INDUCED AMYLOID CLEARANCE; (4) PROVIDING A FOUNDATION FOR UNDERSTANDING THE LONGER TERM CLINICAL IMPACT OF THE INTERVENTIONS LEVERAGING THE COLOMBIAN API REGISTRY; AND (5) PROVIDING INVALUABLE DATA AND SAMPLES FOR THE FIELD.
Department of Health and Human Services
$33.3M
ALZHEIMER'S PREVENTION INITIATIVE APOE4 TRIAL
Department of Health and Human Services
$28.8M
ADUCANUMAB ALZHEIMER'S PREVENTION TRIAL
Department of Health and Human Services
$27.4M
APOE IN THE PREDISPOSITION TO, PROTECTION FROM AND PREVENTION OF ALZHEIMER'S DISEASE
Department of Health and Human Services
$20.3M
ARIZONA ALZHEIMER'S DISEASE RESEARCH CENTER - OVERALL — PROJECT SUMMARY/ABSTRACT OVER THE LAST 20 YEARS, ARIZONA RESEARCHERS ESTABLISHED NIA'S FIRST STATEWIDE ALZHEIMER'S DISEASE CENTER AND THE NATION'S MOST EXTENSIVE STATEWIDE COLLABORATION IN ALZHEIMER'S DISEASE (AD) RESEARCH. THEY MADE PIONEERING CONTRIBUTIONS TO THE UNUSUALLY EARLY DETECTION, TRACKING AND STUDY OF AD AND THE ACCELERATED EVALUATION OF AD PREVENTION THERAPIES. THE CENTER INCLUDES RESEARCHERS FROM SEVEN ORGANIZATIONS, SIX IN THE PHOENIX METROPOLITAN AREA AND ONE IN TUCSON. IT HAS SUPPORTED 150 RESEARCHERS FROM ORGANIZATIONS ACROSS THE STATE AND HELPING THEM TO GENERATE MORE THAN $2 BILLION IN NEW GRANTS, CONTRACTS, PHILANTHROPIC, STATE AND ORGANIZATIONAL INVESTMENTS. THE ARIZONA AD RESEARCH CENTER (ADRC) WILL CAPITALIZE ON THE CENTER'S LEADERSHIP, STATEWIDE COLLABORATIVE MODEL, MAJOR ORGANIZATIONAL COMMITMENTS, AND EXTENSIVELY SHARED SCIENTIFIC RESOURCES AND ITS VERY EXISTENCE TO MAKE THE SCIENTIFIC FIGHT AGAINST AD A TOP PRIORITY IN THE STATE. ITS RESOURCES, STRATEGIC PLAN, AND RELATED PROGRAMS AND PREVENTION TRIALS ARE SPECIFICALLY INTENDED TO SET THE STAGE FOR PROMISING BLOOD TESTS TO TRANSFORM AD/ADRD RESEARCH, TREATMENT DEVELOPMENT, AND CARE, INCLUDE PERSONS FROM DIVERSE BACKGROUNDS, FIND AN EFFECTIVE PREVENTION THERAPY BY 2025, AND FULFILL NATIONAL ALZHEIMER'S PROJECT ACT (NAPA) GOALS. WE WILL USE ADRC, ORGANIZATIONAL AND PHILANTHROPIC FUNDS TO PROVIDE AN EXTRAORDINARY RESOURCE OF DATA AND BLOOD SAMPLES FOR NEUROPATHOLOGICAL STUDY AND DIAGNOSTIC VALIDATION OF BBBS FOR ADRD USING BLOOD SAMPLES FROM SEVERAL HUNDRED BRAIN DONORS IN THE LAST YEARS OF LIFE WHO HAVE COMPREHENSIVE NEUROPATHOLOGICAL ASSESSMENTS AFTER THEY DIE. THE OVERALL GOALS OF THE CENTER WILL BE ACCOMPLISHED THROUGH COORDINATED ACTIVITIES OF ITS SIX CORES AND THE RESEARCH EDUCATION COMPONENT (REC). THE ADMINISTRATIVE CORE WILL PROVIDE THE SCIENTIFIC LEADERSHIP TO THE ADRC AS A WHOLE. THE MULTI-SITE CLINICAL CORE WILL PERFORM STANDARD EVALUATIONS AND COLLECT UDS AND ADDITIONAL DATA ON ALL PARTICIPANTS, INCLUDING A LARGE NUMBER OF HISPANIC/LATINO AND NATIVE AMERICAN PARTICIPANTS. THE NEUROPATHOLOGY CORE WILL PROVIDE NEUROPATHOLOGIC DIAGNOSES AND PROCESS, STORE AND DISTRIBUTE POSTMORTEM BRAIN TISSUE, INCLUDING FROM THOSE WHO PROVIDED BLOOD SAMPLES IN THE LAST 1-2 YEARS OF THEIR LIVES. THE BIOMARKER CORE WILL SUPPORT AND PROVIDE ACCESS TO GENETICS, BRAIN IMAGING (MRI, AMYLOID PET, TAU PET), CEREBROSPINAL FLUID (CSF) AND BBBS OF AD. THE OUTREACH, RECRUITMENT AND ENGAGEMENT (ORE) CORE WILL SUPPORT THE EFFORTS OF THE CLINICAL AND NEUROPATHOLOGY CORE, PROVIDING A RANGE OF EDUCATIONAL AND OUTREACH PROGRAMS FOR HEALTHY ADULTS, PATIENTS AND FAMILY CAREGIVERS IN OUR CENTER'S CATCHMENT AREA, INCLUDING FROM ARIZONA'S LARGE HISPANIC/LATINO AND NATIVE AMERICAN COMMUNITIES. THE DATA MANAGEMENT AND STATISTICS CORE WILL SUPPORT ALL THE DATA MANAGEMENT, INFORMATICS AND STATISTICAL NEEDS OF THE CORES AND CENTER. THE REC WILL COORDINATE CLOSELY WITH EACH OF THE CORES AND LEVERAGE EXTERNAL PARTNERSHIP WITH TWO RESOURCE CENTERS FOR MINORITY AGING RESEARCH (RCMARS) TO ATTRACT AND SUPPORT THE DEVELOPMENT OF NEW RESEARCHERS AND CLINICIANS. TOGETHER THESE ACTIVITIES WILL HELP SET THE STAGE FOR BBBS TO REVOLUTIONIZE ADRD RESEARCH, TREATMENT AND CARE, INFORM THE STUDY OF PRECLINICAL AD, AND HELP PROVIDE THE BEST POSSIBLE CHANGE TO FIND AND SUPPORT THE APPROVAL OF AN AD PREVENTION THERAPY IN 2025.
Department of Health and Human Services
$16.4M
PET, APOE & THE PRECLINICAL COURSE OF ALZHEIMER'S DISEASE
Department of Health and Human Services
$15.3M
ALZHEIMER'S PREVENTION INITIATIVE
Department of Health and Human Services
$14.7M
ALZHEIMER'S PREVENTION INITIATIVE ADAD COLOMBIA TRIAL
Department of Health and Human Services
$9.5M
ESTABLISHING THE SCIENCE BEHIND ALZHEIMER'S RECRUITMENT REGISTRIES: OPPORTUNITIES FOR INCREASING DIVERSITY AND ACCELERATING ENROLLMENT INTO TRIALS
Department of Health and Human Services
$7.4M
NATIONAL BRAIN AND TISSUE RESOURCE FOR PARKINSON'S DISEASE AND RELATED DISORDERS
Department of Health and Human Services
$6.5M
CYCLOTRON PET AND MRI FACILITY IMPROVEMENT: A SCIENTIFIC RESOURCE FOR ARIZONA
Department of Health and Human Services
$3.9M
OPTIMIZING RESEARCH INFRASTRUCTURE OF REGISTRIES TO ACCELERATE PARTICIPANT RECRUITMENT INTO ALZHEIMER'S FOCUSED STUDIES - PROJECT SUMMARY/ABSTRACT THE SUFFERING CAUSED BY ALZHEIMER'S DISEASE (AD) IS ONE OF THE GREATEST MEDICAL CHALLENGES OF OUR TIME. WITH A HEIGHTENED SENSE OF URGENCY, NUMEROUS AD PREVENTION TRIALS ARE BEING LAUNCHED, REQUIRING AN UNPRECEDENTED NUMBER OF HEALTHY OLDER ADULTS TO BE SCREENED TO IDENTIFY THE THOUSANDS ELIGIBLE TO PARTICIPATE. AT THE SAME TIME, THE NUMBER OF TRIALS IN AFFECTED INDIVIDUALS AND THEIR CARE PARTNERS CONTINUES TO RISE. IN 2019, THERE WERE 156 TRIALS FOR THE TREATMENT OF AD, AN INCREASE FROM 2018. NOTABLY, THIS NUMBER DOES NOT INCLUDE OBSERVATIONAL STUDIES, WHICH ARE ALSO IMPORTANT TO UNDERSTANDING AD AND DEVELOPING NEW INTERVENTIONS TO TREAT OR PREVENT IT. IMPROVING PARTICIPANT RECRUITMENT METHODS HAS BECOME A CRITICAL PRIORITY FOR THE FIELD. INITIATIVES SUCH AS THE NATIONAL PLAN TO ADDRESS AD CALL FOR GREATER ATTENTION TO INCREASING ENROLLMENT INTO CLINICAL TRIALS AND OTHER CLINICAL RESEARCH. AN OUTGROWTH OF THE NATIONAL PLAN IS THE NATIONAL STRATEGY FOR RECRUITMENT AND PARTICIPATION IN ALZHEIMER'S DISEASE CLINICAL RESEARCH WHICH ENUMERATED FOUR GOALS, ONE OF WHICH IS FOCUSED SPECIFICALLY ON THE NEED TO “BUILD AND IMPROVE RESEARCH INFRASTRUCTURE OF REGISTRIES IN ORDER TO RECRUIT AND RETAIN MORE AND MORE DIVERSE QUALIFIED STUDY PARTICIPANTS.” THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP, DEPLOY, OPTIMIZE AND AUTOMATE NEW WEBSITE DESIGN/CONTENT, INFRASTRUCTURE AND FUNCTIONALITY TO SUPPORT AND SUSTAIN ONLINE RECRUITMENT, ENGAGEMENT, AND RETENTION OF ADULTS INTERESTED IN PARTICIPATING IN AD-FOCUSED STUDIES, CREATING A SUSTAINABLE AND ENDURING RESOURCE TO RESEARCHERS. TO ACCOMPLISH THIS, WE WILL BUILD OFF OUR SUCCESSFUL ALZHEIMER'S PREVENTION REGISTRY (APR), AN ONLINE REGISTRY LAUNCHED IN 2012 WITH >350,000 MEMBERS, INCLUDING ~90,000 ENROLLED IN ITS GENEMATCH (GM) PROGRAM LAUNCHED IN 2015 VIA THE FOLLOWING AIMS: 1) DEVELOP, DEPLOY, OPTIMIZE AND AUTOMATE A REFRESHED AND SUSTAINABLE WEBSITE PLATFORM FOR THE RECRUITMENT INTO AND ENGAGEMENT OF MEMBERS IN THE APR AND ITS GM PROGRAM; 2) DEVELOP, DEPLOY, OPTIMIZE AND AUTOMATE A REFRESHED WEBSITE PLATFORM SUPPORTING RESEARCHERS' EFFORTS TO RECRUIT APR AND GM MEMBERS; AND 3) DEVELOP, DEPLOY, OPTIMIZE AND AUTOMATE NEW FUNCTIONALITY AND PROCESSES FOR REFERRING APR AND GM MEMBERS TO AD- FOCUSED STUDIES. WE HYPOTHESIZE THAT THE A) REFRESHED WEBSITE WILL INCREASE ENROLLMENT INTO THE APR AND GM AS WELL AS ENGAGEMENT AND RETENTION OF MEMBERS; B) ENHANCED AD-RESEARCHER EXPERIENCE WILL INCREASE THE NUMBER OF RESEARCHERS / STUDY SPONSORS LEVERAGING THE APR/GM FOR THEIR PARTICIPANT RECRUITMENT NEEDS, ALLOWING THEM TO COMPLETE ENROLLMENT FASTER; AND C) NEW FUNCTIONALITY WILL INCREASE THE PERCENTAGE OF APR AND GM MEMBERS SCREENING FOR AND ENROLLING IN AD-FOCUSED STUDIES.
Department of Health and Human Services
$2.7M
THE GE PETTRACE CYCLOTRON: A SCIENTIFIC RESOURCE FOR THE STATE OF ARIZONA
Department of Health and Human Services
$2.3M
BLINDED COMPARISON OF DIFFERENT ALPHA-SYNUCLEIN SEEDING ASSAYS AS CUTANEOUS BIOMARKERS OF LEWY BODY DEMENTIAS - ABSTRACT WITH INCREASING LONGEVITY IN OUR POPULATION, DEMENTIA IS WIDELY RECOGNIZED AS AN IMPENDING PUBLIC HEALTH CRISIS. LEWY BODY DEMENTIA (LBD), ENCOMPASSING DEMENTIA WITH LEWY BODIES (DLB) AND PARKINSON DISEASE DEMENTIA (PDD), IS THE SECOND MOST COMMON CAUSE. LBD IS CHARACTERIZED BY ABNORMAL AGGREGATION AND ACCUMULATION OF A PROTEIN, A-SYNUCLEIN (ASYN). PDD AND DLB ARE CLINICALLY SEPARATED ONLY BY THE RELATIVE TIMING OF THE ONSET OF PARKINSONISM AND DEMENTIA. AT PRESENT, ADVANCES IN THE TREATMENT OF THESE CONDITIONS ARE CRITICALLY HAMPERED BY THE LACK OF NON-INVASIVE, INEXPENSIVE BIOMARKERS THAT CAN PROVIDE ACCURATE DIAGNOSTIC AND PROGNOSTIC INFORMATION. THIS SITUATION MAY SOON BE RESOLVED, AS IN RECENT YEARS IT HAS BECOME APPARENT, THROUGH OUR OWN STUDIES AND THOSE OF OTHERS, THAT BIOPSIES OF PERIPHERAL TISSUE SITES CAN DETECT DIAGNOSTICALLY SIGNIFICANT ASYN. OUR PROJECT WILL ASSESS ASYN IN PUNCH BIOPSIES OF THE SKIN. OUR PRELIMINARY DATA FROM NEW “SEEDING ASSAY” METHODS INCLUDING REAL-TIME QUAKING-INDUCED CONVERSION (RT-QUIC) AND PROTEIN MISFOLDING CYCLIC AMPLIFICATION (PMCA), FROM AUTOPSY-CONFIRMED LBD SUBJECTS, INDICATE HIGH SENSITIVITY AND SPECIFICITY FOR PREDICTING THE PRESENCE OF ASYN IN THE SKIN OF AFFECTED SUBJECTS. FURTHER WORK IS NECESSARY TO CONFIRM THESE RESULTS IN LIVING SUBJECTS WITH THESE CONDITIONS, WHICH IS THE OBJECTIVE OF THIS PROPOSED PROJECT. WE WILL BIOPSY, TWICE DURING A FOUR YEAR PERIOD, 90 SUBJECTS WITH ASYN DISEASE, 30 EACH WITH PD, PDD AND DLB, AS WELL AS 30 NORMAL CONTROL SUBJECTS. TWO INDEPENDENT LABORATORIES WILL BLINDLY PERFORM SEPARATELY-DEVELOPED SEEDING ASSAYS, RIGOROUSLY TESTING THE INTERLABORATORY RELIABILITY AND PROVIDING ESTIMATES OF ASYN DENSITY CHANGE OVER TIME. THE SEEDING ASSAY RESULTS WILL BE COMPARED WITH THOSE OBTAINED BY THE CURRENT GOLD-STANDARD BIOPSY METHOD, IMMUNOHISTOCHEMISTRY (IHC). ALL SUBJECTS WILL RECEIVE COGNITIVE AND MOVEMENT DISORDER ASSESSMENTS AT TWO TIMEPOINTS IN THIS FOUR YEAR PROJECT, ENABLING COMPARISONS OF ASSAY MEASURES WITH COGNITIVE AND MOTOR DECLINE RATES. MANY OF THE SUBJECTS WILL BE ENROLLED IN THE ARIZONA STUDY OF AGING AND NEURODEGENERATIVE DISORDERS (AZSAND), A LONGITUDINAL CLINICOPATHOLOGICAL STUDY WITH AN AUTOPSY RATE EXCEEDING 90%. THIS WILL ALLOW, IN A SUBSTANTIAL SUBSET, EVENTUAL NEUROPATHOLOGICAL CONFIRMATION OF THE MOLECULAR CAUSE OF PARKINSONISM AND DEMENTIA IN EACH SUBJECT.
Department of Health and Human Services
$2.3M
TRACER HARMONIZATION FOR AMYLOID AND TAU PET IMAGING USING STATISTICAL AND DEEP LEARNING TECHNIQUES - PROJECT SUMMARY/ABSTRACT AMYLOID AND TAU ARE TWO HALLMARK PATHOLOGIES OF ALZHEIMER'S DISEASE (AD), WHICH START TO ACCUMULATE IN THE BRAIN LONG BEFORE CLINICAL SYMPTOM ONSET. WITH THE RECENT DEVELOPMENT OF POSITRON EMISSION TOMOGRAPHY (PET) TRACERS, IN VIVO MEASUREMENTS OF THESE TWO PATHOLOGIES BECAME POSSIBLE AND PLAY IMPORTANT ROLES IN IMPROVING OUR UNDERSTANDING OF AD PATHOGENESIS AND PROGRESSION, AND PROVIDE CRITICAL DIAGNOSTIC AND PROGNOSTIC INFORMATION THAT CAN FACILITATE THE TREATMENT DEVELOPMENT EFFORT NOW AND IMPROVE PATIENT OUTCOME WHEN EFFECTIVE TREATMENTS BECOME AVAILABLE. HOWEVER, MULTIPLE PET TRACERS EXIST FOR BOTH AMYLOID AND TAU IMAGING AND GENERATE IMAGES THAT HAVE DIFFERENT VISUAL APPEARANCES AND QUANTITATIVE CHARACTERISTICS. THESE DIFFERENCES LEAD TO DIFFICULTIES IN COMPARING DIFFERENT STUDIES, LEVERAGING THE LARGE VOLUME OF DATA THAT HAVE BEEN COLLECTED TO DATE, AND DEFINING A COMMON CRITERION FOR POSITIVITY. IN THIS PROJECT, WE WILL FOCUS ON THE DEVELOPMENT OF NOVEL TECHNIQUES THAT CAN HARMONIZE PET IMAGING DATA AND GENERATE HIGHLY COMPATIBLE IMAGING DERIVED MEASUREMENTS. WE ARGUE THAT BY ADOPTING ADVANCED STATISTICAL AND DEEP LEARNING TECHNIQUES AND DEVELOPING NOVEL QUANTIFICATION STRATEGIES THAT TAKE FULL USE OF THE AVAILABLE INFORMATION IN IMAGING DATA, SUCCESSFUL HARMONIZATION CAN BE ACHIEVED VIA GENERALIZABLE APPROACHES. SEVERAL LINES OF RESEARCH SUPPORT THIS ARGUMENT: 1) WE RECENTLY DEMONSTRATED THAT USING PARTIAL VOLUME CORRECTION TECHNIQUE TO REDUCE WHITE MATTER SIGNAL CONTAMINATION, IMPROVED AGREEMENTS IN AMYLOID BURDEN MEASUREMENTS DERIVED FROM PIB AND FLORBETAPIR CAN BE OBTAINED; 2) IN OUR PRELIMINARY ANALYSIS, USING MACHINE LEARNING TECHNIQUE, WE CAN SUBSTANTIALLY IMPROVE BETWEEN-TRACER AGREEMENTS IN GLOBAL AMYLOID BURDEN; 3) RECENT ADVANCEMENT IN DEEP LEARNING RESEARCH DEMONSTRATED THE ABILITY TO “IMPUTE” ONE IMAGING MODALITY FROM ANOTHER BY TAKING ADVANTAGE OF THE INHERENT INFORMATION IN LARGE IMAGING DATASETS, AND OUR PRELIMINARY RESULTS DEMONSTRATED ITS POTENTIAL IN IMAGE HARMONIZATION TASKS. IN THIS PROJECT, WE WILL CONTINUE THIS RESEARCH AND DEVELOP A SET OF TECHNIQUES THAT CAN BE USED TO HARMONIZE AMYLOID IMAGING DATA FROM DIFFERENT TRACERS AND EXTENT THIS APPROACH FOR TAU PET HARMONIZATION. OUR SPECIFIC AIMS ARE 1) TO DEVELOP DEEP LEARNING MODELS THAT CAN GENERATE IMPUTED AMYLOID PET IMAGES FROM ONE TRACER BASED ON THE IMAGES FROM ANOTHER TRACER; 2) TO DEVELOP STATISTICAL LEARNING APPROACHES THAT CAN GENERATE HARMONIZED AMYLOID BURDEN MEASUREMENTS; 3) TO ACQUIRE HEAD-TO-HEAD COMPARISON TAU PET IMAGING DATA AND EXAMINE STATISTICAL AND DEEP LEARNING APPROACHES TO THE HARMONIZATION OF TAU PET IMAGING DATA.
Department of Health and Human Services
$2M
DNA METHYLATION IN ALZHEIMER?S DISEASE AND NORMALLY AGED BRAIN
Department of Defense
$1.8M
SOCIALLY RELEVANT KNOWLEDGE BASED TELEMEDICINE
Department of Health and Human Services
$1.4M
TRACER HARMONIZATION FOR AMYLOID AND TAU PET IMAGING USING STATISTICAL AND DEEP LEARNING TECHNIQUES - PROJECT SUMMARY/ABSTRACT AMYLOID AND TAU ARE TWO HALLMARK PATHOLOGIES OF ALZHEIMER'S DISEASE (AD), WHICH START TO ACCUMULATE IN THE BRAIN LONG BEFORE CLINICAL SYMPTOM ONSET. WITH THE RECENT DEVELOPMENT OF POSITRON EMISSION TOMOGRAPHY (PET) TRACERS, IN VIVO MEASUREMENTS OF THESE TWO PATHOLOGIES BECAME POSSIBLE AND PLAY IMPORTANT ROLES IN IMPROVING OUR UNDERSTANDING OF AD PATHOGENESIS AND PROGRESSION, AND PROVIDE CRITICAL DIAGNOSTIC AND PROGNOSTIC INFORMATION THAT CAN FACILITATE THE TREATMENT DEVELOPMENT EFFORT NOW AND IMPROVE PATIENT OUTCOME WHEN EFFECTIVE TREATMENTS BECOME AVAILABLE. HOWEVER, MULTIPLE PET TRACERS EXIST FOR BOTH AMYLOID AND TAU IMAGING AND GENERATE IMAGES THAT HAVE DIFFERENT VISUAL APPEARANCES AND QUANTITATIVE CHARACTERISTICS. THESE DIFFERENCES LEAD TO DIFFICULTIES IN COMPARING DIFFERENT STUDIES, LEVERAGING THE LARGE VOLUME OF DATA THAT HAVE BEEN COLLECTED TO DATE, AND DEFINING A COMMON CRITERION FOR POSITIVITY. IN THIS PROJECT, WE WILL FOCUS ON THE DEVELOPMENT OF NOVEL TECHNIQUES THAT CAN HARMONIZE PET IMAGING DATA AND GENERATE HIGHLY COMPATIBLE IMAGING DERIVED MEASUREMENTS. WE ARGUE THAT BY ADOPTING ADVANCED STATISTICAL AND DEEP LEARNING TECHNIQUES AND DEVELOPING NOVEL QUANTIFICATION STRATEGIES THAT TAKE FULL USE OF THE AVAILABLE INFORMATION IN IMAGING DATA, SUCCESSFUL HARMONIZATION CAN BE ACHIEVED VIA GENERALIZABLE APPROACHES. SEVERAL LINES OF RESEARCH SUPPORT THIS ARGUMENT: 1) WE RECENTLY DEMONSTRATED THAT USING PARTIAL VOLUME CORRECTION TECHNIQUE TO REDUCE WHITE MATTER SIGNAL CONTAMINATION, IMPROVED AGREEMENTS IN AMYLOID BURDEN MEASUREMENTS DERIVED FROM PIB AND FLORBETAPIR CAN BE OBTAINED; 2) IN OUR PRELIMINARY ANALYSIS, USING MACHINE LEARNING TECHNIQUE, WE CAN SUBSTANTIALLY IMPROVE BETWEEN-TRACER AGREEMENTS IN GLOBAL AMYLOID BURDEN; 3) RECENT ADVANCEMENT IN DEEP LEARNING RESEARCH DEMONSTRATED THE ABILITY TO “IMPUTE” ONE IMAGING MODALITY FROM ANOTHER BY TAKING ADVANTAGE OF THE INHERENT INFORMATION IN LARGE IMAGING DATASETS, AND OUR PRELIMINARY RESULTS DEMONSTRATED ITS POTENTIAL IN IMAGE HARMONIZATION TASKS. IN THIS PROJECT, WE WILL CONTINUE THIS RESEARCH AND DEVELOP A SET OF TECHNIQUES THAT CAN BE USED TO HARMONIZE AMYLOID IMAGING DATA FROM DIFFERENT TRACERS AND EXTENT THIS APPROACH FOR TAU PET HARMONIZATION. OUR SPECIFIC AIMS ARE 1) TO DEVELOP DEEP LEARNING MODELS THAT CAN GENERATE IMPUTED AMYLOID PET IMAGES FROM ONE TRACER BASED ON THE IMAGES FROM ANOTHER TRACER; 2) TO DEVELOP STATISTICAL LEARNING APPROACHES THAT CAN GENERATE HARMONIZED AMYLOID BURDEN MEASUREMENTS; 3) TO ACQUIRE HEAD-TO-HEAD COMPARISON TAU PET IMAGING DATA AND EXAMINE STATISTICAL AND DEEP LEARNING APPROACHES TO THE HARMONIZATION OF TAU PET IMAGING DATA.
Department of Labor
$717K
SEE NOTICE OF AWARD, ATTACHMENT 1 - TERMS AND CONDITIONS, ATTACHMENT D, STATEMENT OF WORK, ABSTRACT
Department of Health and Human Services
$397.3K
ARE THE SUPPRESSORS OF CYTOKINE SIGNALING INVOLVED IN ALZHEIMER'S DISEASE?
Department of Health and Human Services
$176.8K
CARDIOVASCULAR GENOTYPE AND APOE ?4 CARRIER STATUS INTERACTION EFFECTS ON AMYLOID LOAD IN PRE-CLINICAL ALZHEIMER'S DISEASE - PROJECT SUMMARY RESEARCH AND TREATMENT APPROACHES IN PRE-CLINICAL ALZHEIMER'S DISEASE (AD) HAVE FOCUSED PRIMARILY ON THE DEPOSITION AND CLEARANCE OF BETA-AMYLOID WHICH LEADS TO THE FORMATION OF CORTICAL PLAQUES AND NEUROFIBRILLARY TANGLES, A HALLMARK OF AD PATHOLOGY. HOWEVER, THE ROLE THAT VASCULAR FACTORS MAY HAVE IN THE DEVELOPMENT OF THESE PATHOLOGIES IS NOT CLEAR. EPIDEMIOLOGICAL STUDIES HAVE SUGGESTED THAT RISK FACTORS SUCH AS HIGH CHOLESTEROL, HYPERTENSION, TYPE 2 DIABETES, AND INFLAMMATION ARE ASSOCIATED WITH AN INCREASED RISK OF DEVELOPING AD. SEVERAL STUDIES HAVE DEMONSTRATED THAT CERTAIN CARDIOVASCULAR GENETIC MARKERS ARE ASSOCIATED WITH CLINICAL AD AND ITS PATHOLOGICAL HALLMARKS. SPECIFIC POLYMORPHISMS OF THE CRP GENE (RS3091244, AND RS3093075) ARE ASSOCIATED WITH GREATER PLAQUE LOAD WHILE THE RS1205 AND RS2794521 POLYMORPHISMS APPEARS TO PROTECT AGAINST AMYLOID DEPOSITION. THE METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) GENE HAS BEEN IMPLICATED AS A SUSCEPTIBILITY MARKER FOR AD AND IS ALSO RECOGNIZED AS AN IMPORTANT FACTOR IN CARDIOVASCULAR DISEASE DUE TO ITS ROLE IN REGULATING HOMOCYSTEINE. THE MTHFR C677T (RS1801133) POLYMORPHISM IS A MARKER OF INTEREST IN BOTH THE AD AND CARDIOVASCULAR CONTEXTS AND IT IS NOTED THAT THIS POLYMORPHISM INTERACTS WITH APOE CARRIER STATUS ON CARDIOVASCULAR OUTCOMES. THERE IS ALSO EVIDENCE THAT THE RS1801131 POLYMORPHISM INFLUENCES THE RISK OF AD AND HAS SHOWN TO MODERATE THE EFFECT OF APOE ON AD RISK. VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) HAS ALSO BEEN IMPLICATED IN AD AS THE C2578A ALLELE (RS699947) HAS BEEN ASSOCIATED WITH AN INCREASED RISK FOR AD IN WHICH A SIGNIFICANT VEGF BY APOE INTERACTION MAY PLAY A ROLE. THE G1154A (RS1570360) POLYMORPHISM OF VEGF HAS SHOWN TO HAVE A PROTECTIVE EFFECT FOR AD. THE KINESIN FAMILY MEMBER 6 (KIF6) GENE'S 719ARG POLYMORPHISM (RS20455) HAS BEEN STRONGLY IMPLICATED IN THE RISK FOR CARDIOVASCULAR EVENTS, BUT ITS POSSIBLE ROLE IN AD HAS NOT BEEN FULLY INVESTIGATED. THE RS3025039 POLYMORPHISM HAS ALSO SHOWN CONSISTENT ASSOCIATIONS WITH CARDIOVASCULAR DISEASE HOWEVER ITS LINK WITH AD RISK OR PATHOLOGY IS UNKNOWN. THE AIM OF THIS STUDY WILL BE TO EXAMINE THE EFFECTS OF THESE CARDIOVASCULAR GENE MARKERS ON IMAGING-BASED MEASURES OF AMYLOID IN COGNITIVELY UNIMPAIRED OLDER ADULTS. THIS STUDY WILL ALSO EXPLORE WHETHER THE INTERACTIONS BETWEEN APOE E4 CARRIER STATUS AND THESE ALLELES ARE ASSOCIATED WITH IN VIVO PLAQUE AND TANGLE LOAD.
Department of Health and Human Services
$148.8K
BOLD AND PERFUSION FMRI OF ALZHEIMER'S DISEASE RISK
Department of Health and Human Services
$100K
RURAL HEALTH NETWORK DEVELOPMENT PLANNING GRANT PROGRAM
Department of Health and Human Services
$85K
RURAL HEALTH NETWORK DEVELOPMENT PLANNING GRANT PROGRAM
Department of Health and Human Services
$4,908
INTEGRATIVE ONCOLOGY: FROM RESEARCH TO PRACTICAL APPLICATIONS
Department of Health and Human Services
$0
PET APOE & THE PRECLINICAL COURSE OF ALZHEIMER DISEASE
Source: Federal Audit Clearinghouse (fac.gov)
Years audited
10
Clean years
9
Material Weakness
Yes
Noncompliance Issues
No
| Year | Status | Financial Report | Federal Expenditurecombined across all audits filed that year | Low Risk | Accepted |
|---|---|---|---|---|---|
| 2025 | Clean | Unmodified (Clean) | $38.4M | No | 2026-09-11 |
| 2024 | Clean | Unmodified (Clean) | $538.5M | Yes | 2025-08-07 |
| 2023 | Clean | Unmodified (Clean) | $139.7M | No | 2024-09-10 |
| 2022 | Clean | Unmodified (Clean) | $68M | No | 2023-09-27 |
| 2021 | Material Weakness | Unmodified (Clean) | $523.2M | No | 2023-01-24 |
| 2020 | Clean | Unmodified (Clean) | $44.8M | Yes | 2022-04-13 |
| 2019 | Clean | Unmodified (Clean) | $9.3M | Yes | 2020-09-15 |
| 2018 | Clean | Unmodified (Clean) | $18.4M | Yes | 2019-09-24 |
| 2017 | Clean | Unmodified (Clean) | $13.5M | Yes | 2018-08-05 |
| 2016 | Clean | Unmodified (Clean) | $16.7M | Yes | 2017-07-27 |
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$38.4M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$538.5M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$139.7M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$68M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$523.2M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$44.8M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$9.3M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$18.4M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$13.5M
Financial Report
Unmodified (Clean)
Federal Expenditure, combined across all audits filed that year
$16.7M
Tax Year 2024 · Source: IRS e-Filed Form 990Schedule J available
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $10.8B | $370.3M | $9.3B | $17.7B | $9.9B |
| 2023IRS e-File | $9.5B | $101M | $8.7B | $15B | $7.8B |
| 2022 | $8.5B | $120.8M | $8.1B | $13.7B | $7B |
| 2021 | $8.8B |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2024)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| Peter S Fine | Chief Executive Officer | 40 | $8.6M | $0 | $5M | $13.5M |
| Amy Perry | President | 40 | $4.6M | $0 | $4.5M | $9.1M |
| Donald Nordlund | Evp, Chief Strategy & Growth Officer | 40 | $2.1M | $0 | $1.1M | $3.2M |
| Jean Fitterer Lance | Evp, Chief Legal Officer & General Counsel | 40 | $2M | $0 | $970K | $2.9M |
| Marjorie Bessel Md | Evp, Chief Clinical Officer | 40 | $1.9M | $0 | $1M | $2.9M |
| Staci Dickerson | Evp, Chief Financial Officer | 40 | $1.7M | $0 | $926.7K | $2.6M |
| Julie A Alvarado-Dubek | Evp, Chief Human Resources Officer | 40 | $1.5M | $0 | $893.6K | $2.4M |
| Josh Groesbeck | Senior VP - Acute Care Comm. Delivery | 40 | $853.8K | $0 | $325.4K | $1.2M |
| Brenda Schaefer | Vp, Chief Investment Officer | 40 | $773.6K | $0 | $135.7K | $909.3K |
| Mary Schubert | Executive Director, Legal Services & Assistant Secretary | 40 | $391.8K | $0 | $23.8K | $415.6K |
| Anne Mariucci | Director/vice-chair | 6 | $161K | $0 | $0 | $161K |
| Quentin P Smith Jr | Director/chairman | 6 | $106.5K | $0 | $0 | $106.5K |
Peter S Fine
Chief Executive Officer
$13.5M
Hrs/Wk
40
Compensation
$8.6M
Related Orgs
$0
Other
$5M
Amy Perry
President
$9.1M
Hrs/Wk
40
Compensation
$4.6M
Related Orgs
$0
Other
$4.5M
Donald Nordlund
Evp, Chief Strategy & Growth Officer
$3.2M
Hrs/Wk
40
Compensation
$2.1M
Related Orgs
$0
Other
$1.1M
Jean Fitterer Lance
Evp, Chief Legal Officer & General Counsel
$2.9M
Hrs/Wk
40
Compensation
$2M
Related Orgs
$0
Other
$970K
Marjorie Bessel Md
Evp, Chief Clinical Officer
$2.9M
Hrs/Wk
40
Compensation
$1.9M
Related Orgs
$0
Other
$1M
Staci Dickerson
Evp, Chief Financial Officer
$2.6M
Hrs/Wk
40
Compensation
$1.7M
Related Orgs
$0
Other
$926.7K
Julie A Alvarado-Dubek
Evp, Chief Human Resources Officer
$2.4M
Hrs/Wk
40
Compensation
$1.5M
Related Orgs
$0
Other
$893.6K
Josh Groesbeck
Senior VP - Acute Care Comm. Delivery
$1.2M
Hrs/Wk
40
Compensation
$853.8K
Related Orgs
$0
Other
$325.4K
Brenda Schaefer
Vp, Chief Investment Officer
$909.3K
Hrs/Wk
40
Compensation
$773.6K
Related Orgs
$0
Other
$135.7K
Mary Schubert
Executive Director, Legal Services & Assistant Secretary
$415.6K
Hrs/Wk
40
Compensation
$391.8K
Related Orgs
$0
Other
$23.8K
Anne Mariucci
Director/vice-chair
$161K
Hrs/Wk
6
Compensation
$161K
Related Orgs
$0
Other
$0
Quentin P Smith Jr
Director/chairman
$106.5K
Hrs/Wk
6
Compensation
$106.5K
Related Orgs
$0
Other
$0
Highest compensated employees who are not officers or directors.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Todd S Werner | Svp, Acute Care Delivery | 40 | $2.1M | $0 | $889.3K | $3M |
| Michael Reagin | Executive Vp, Chief Technology Officer | 40 | $1.2M | $0 | $418K | $1.6M |
| Margo Karsten | Division President | 40 | $1.1M | $0 |
Todd S Werner
Svp, Acute Care Delivery
$3M
Hrs/Wk
40
Compensation
$2.1M
Related Orgs
$0
Other
$889.3K
Michael Reagin
Executive Vp, Chief Technology Officer
$1.6M
Hrs/Wk
40
Compensation
$1.2M
Related Orgs
$0
Other
$418K
Margo Karsten
Division President
$1.5M
Hrs/Wk
40
Compensation
$1.1M
Related Orgs
$0
Other
$387K
Members of the governing board. Board members often serve without compensation.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| Christopher Volk | Director | 4 | $102.5K | $0 | $0 | $102.5K |
| David Kikumoto | Director (thru 08/24) | 4 | $43.5K | $0 | $0 | $43.5K |
| Dean Harrison | Director | 4 | $90.5K | $0 | $0 | $90.5K |
| Gilbert Davila | Director | 4 | $102.5K | $0 | $0 | $102.5K |
| John Koster Md | Director | 4 | $98.5K | $0 | $0 | $98.5K |
| Mark Wallace | Director |
Christopher Volk
Director
$102.5K
Hrs/Wk
4
Compensation
$102.5K
Related Orgs
$0
Other
$0
David Kikumoto
Director (thru 08/24)
$43.5K
Hrs/Wk
4
Compensation
$43.5K
Related Orgs
$0
Other
$0
Dean Harrison
Director
$90.5K
Hrs/Wk
4
Compensation
$90.5K
Related Orgs
$0
Other
$0
Individuals who previously served as officers or key employees.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other | Total |
|---|---|---|---|---|---|---|
| David Bixby | Former Officer | — | $258.4K | $0 | $76.2K | $334.7K |
| Rebecca Kuhn | Former Officer | — | $280.6K | $0 | $0 | $280.6K |
David Bixby
Former Officer
$334.7K
Hrs/Wk
—
Compensation
$258.4K
Related Orgs
$0
Other
$76.2K
Rebecca Kuhn
Former Officer
$280.6K
Hrs/Wk
—
Compensation
$280.6K
Related Orgs
$0
Other
$0
| $167.6M |
| $8.1B |
| $14.9B |
| $7.6B |
| 2020 | $7.5B | $336.9M | $7B | $14.5B | $7B |
| 2019 | $7.1B | $36.3M | $6.5B | $12.6B | $6.8B |
| 2018 | $6.8B | $42.4M | $6B | $11B | $5.9B |
| 2017 | $6.5B | $34.1M | $5.8B | $11.2B | $5.8B |
| 2016 | $6.3B | $97M | $5.8B | $9.9B | $5B |
| 2015 | $5.9B | $38.5M | $5.4B | $9.5B | $4.6B |
| 2014 | $4.8B | $27.4M | $4.4B | $8.3B | $4.5B |
| 2013 | $4.5B | $36.8M | $4B | $7.8B | $4.2B |
| 2012 | $4.3B | $14.8M | $3.8B | $7.2B | $3.3B |
| 2011 | $4.2B | $9.4M | $3.9B | $6.3B | $2.7B |
| 2021 | 990 | Data |
| 2020 | 990 | Data | PDF not yet published by IRS |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2006 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |
| $387K |
| $1.5M |
| Deanna Wise | Svp, Chief Information Officer (thru 03/24) | 40 | $1.4M | $0 | $9,853 | $1.5M |
| Daniel Post | Chief Executive Officer - Large Facility | 40 | $1.2M | $0 | $214.5K | $1.4M |
| Laura Robertson | Chief Executive Officer - Large Facility | 40 | $1.1M | $0 | $211.5K | $1.3M |
| Debra Flores | Chief Executive Officer - Large Facility | 40 | $1M | $0 | $154.1K | $1.2M |
| Matthew Callister | Senior Physician Executive Oncology & Bmdacc | 40 | $1M | $0 | $99.2K | $1.1M |
| Ramanjit Dhaliwal | Vp, Cmo Delivery | 40 | $957.9K | $0 | $174.8K | $1.1M |
| Charles Bowen | Svp, Chief Supply Chain Officer (thru 01/24) | 40 | $1M | $0 | $75K | $1.1M |
| Lamont Yoder | Division President | 40 | $771.3K | $0 | $15.8K | $787K |
| Sarah Frost | Chief Executive Officer - Large Facility (thru 04/24) | 40 | $618.9K | $0 | $7,423 | $626.3K |
Deanna Wise
Svp, Chief Information Officer (thru 03/24)
$1.5M
Hrs/Wk
40
Compensation
$1.4M
Related Orgs
$0
Other
$9,853
Daniel Post
Chief Executive Officer - Large Facility
$1.4M
Hrs/Wk
40
Compensation
$1.2M
Related Orgs
$0
Other
$214.5K
Laura Robertson
Chief Executive Officer - Large Facility
$1.3M
Hrs/Wk
40
Compensation
$1.1M
Related Orgs
$0
Other
$211.5K
Debra Flores
Chief Executive Officer - Large Facility
$1.2M
Hrs/Wk
40
Compensation
$1M
Related Orgs
$0
Other
$154.1K
Matthew Callister
Senior Physician Executive Oncology & Bmdacc
$1.1M
Hrs/Wk
40
Compensation
$1M
Related Orgs
$0
Other
$99.2K
Ramanjit Dhaliwal
Vp, Cmo Delivery
$1.1M
Hrs/Wk
40
Compensation
$957.9K
Related Orgs
$0
Other
$174.8K
Charles Bowen
Svp, Chief Supply Chain Officer (thru 01/24)
$1.1M
Hrs/Wk
40
Compensation
$1M
Related Orgs
$0
Other
$75K
Lamont Yoder
Division President
$787K
Hrs/Wk
40
Compensation
$771.3K
Related Orgs
$0
Other
$15.8K
Sarah Frost
Chief Executive Officer - Large Facility (thru 04/24)
$626.3K
Hrs/Wk
40
Compensation
$618.9K
Related Orgs
$0
Other
$7,423
| 4 |
| $98.5K |
| $0 |
| $0 |
| $98.5K |
| Michael Garnreiter | Director | 4 | $90.5K | $0 | $0 | $90.5K |
| Rick Myers | Director | 4 | $90.5K | $0 | $0 | $90.5K |
| Sara Ward | Director | 4 | $90.5K | $0 | $0 | $90.5K |
| Sujata Gosalia | Director | 4 | $98.5K | $0 | $0 | $98.5K |
| Vicki Keiser | Director | 4 | $108K | $0 | $0 | $108K |
Gilbert Davila
Director
$102.5K
Hrs/Wk
4
Compensation
$102.5K
Related Orgs
$0
Other
$0
John Koster Md
Director
$98.5K
Hrs/Wk
4
Compensation
$98.5K
Related Orgs
$0
Other
$0
Mark Wallace
Director
$98.5K
Hrs/Wk
4
Compensation
$98.5K
Related Orgs
$0
Other
$0
Michael Garnreiter
Director
$90.5K
Hrs/Wk
4
Compensation
$90.5K
Related Orgs
$0
Other
$0
Rick Myers
Director
$90.5K
Hrs/Wk
4
Compensation
$90.5K
Related Orgs
$0
Other
$0
Sara Ward
Director
$90.5K
Hrs/Wk
4
Compensation
$90.5K
Related Orgs
$0
Other
$0
Sujata Gosalia
Director
$98.5K
Hrs/Wk
4
Compensation
$98.5K
Related Orgs
$0
Other
$0
Vicki Keiser
Director
$108K
Hrs/Wk
4
Compensation
$108K
Related Orgs
$0
Other
$0